ons regenerate after injury. It has been demonstrated that this electrical effect is mediated via membrane-bound receptors, and secondary messengers such as adenylate cyclase and neuropeptides, and is linked to additional guidance cues provided by physiological substrates. 16, 18, 21, 26 It has been demonstrated in a study involving an in vivo severed sea lamprey spinal cord that an implanted cathode facilitated functional axonal regeneration toward the cathode. 3 Strautman, et al., 27 documented that the cathode led to a reduction of the cytodestructive effects of an endogenous calcium current of injury into damaged nerve fibers, which explained earlier measurements of a marked reduction in degeneration of the axonal tip when facing cathodes but not anodes. 23 In a mammalian model of SCI involving the rat and guinea pig, the application of a 400-V/mm electrical field for 3 weeks facilitated axonal regeneration histologically and led to functional improvement as measured by a cutaneous trunci muscle reflex. 1, 2 The cathode was placed rostral to the injury and only sensory recovery was demonstrated. Additionally, these investigators demonstrated a reduction in the number of astrocytes at the level of the SCI and showed that astrocytes oriented their processes parallel to the electrical field. 19 No effect on macrophages was observed. It follows that an applied electrical field might also lessen gliosis at the injury site. In additional mammalian studies conducted by independent investigators at another laboratory these results were confirmed in a rat model of compression-related SCI. 10, 28 The placement of a cathode rostral or caudal to the site of an SCI will only facilitate regeneration in one direction. Thus, to facilitate regeneration of rostrally directed sensory fibers and caudally directed motor fibers, a stimulator was created that would oscillate polarity every 15 minutes. This stimulator was designed for application in humans but was first tested in a canine with naturally occurring SCI due to herniated thoracolumbar discs. Many pet dogs, especially the dachshund, basset, and beagle, are susceptible to explosive disc herniation and develop a rapidly progressing complete SCI. 8 This complete SCI has been systematically studied and reported in the veterinary literature and is termed a Hansen Type 1 lesion. 8 The prognosis is poor despite the provision by veterinary neurosurgeons of emergency intravenous methylprednisolone, immediate imaging, and surgery. 9 The surgical procedure includes a laminectomy and discectomy performed exactly as in humans. Sixty percent of Hansen Type 1 dogs remain completely paraplegic, and 25% of dogs recover variable locomotion. Two prospective randomized controlled trials have been conducted to compare the use of an implanted extraspinal OFS and steroid therapy/surgery with a sham OFS combined with steroid therapy/surgery in Hansen Type 1 dogs at the Purdue School of Veterinary Medicine. 5, 6 The OFS consisted of three leads sutured to the bilateral facet joints and spinous processes one segment above the level of injury and three other leads placed in the same manner one segment below the level of injury; both groups of leads are connected to the oscillating electrical field generator that was implanted subcutaneously in the paraspinous musculature. The OFS was left in place for 14 weeks, explanted, and studied. The animals were evaluated at many time points. Investigators in both trials documented statistically significant greater neurological recovery in the OFS-treated group (no morbidity) compared with that in the control dogs. The device proved to be durable and safe. Also learned in all of the aforecited studies was that the treatment must be initiated within 18 days of injury to induce neurological recovery; placement of an OFS after 18 days yielded no improvement in neurological recovery.
Human OFSs were manufactured at the Center for Paralysis Research at Purdue University and tested extensively for fail-safe safety and durability. A study for application of OFS in patients with neurologically complete SCI was given institutional review board approval and an FDA investigational device exemption number was obtained. It was the opinion of the FDA that a Phase 1 study should first be performed in 10 patients for safety evaluation before proceeding with any randomized trial. Here we present the results obtained in 10 patients with neurologically complete SCIs who underwent implantation of an OFS.
Clinical Material and Methods

Device Description
The outside case of the OFS is made of a fluoropolymer and silicone sealant that have both been used in other human applications (Fig. 1) . Inside the case are the power block, timing/switching block, current regulation block, and fail-safe device. The electronic schematic, details of fabrication, and electrical operation of the OFS have been reported. 6 Briefly, the power block provides the direct-current power source for the unit involving a single 3.6-V organic lithium battery with a rated capacity of 2400 mAmp/hour. The timing/switching block consisted of a complementary metal oxide semiconductor 14-stage binary ripple counter device with an onboard oscillator timed for 15-minute intervals along with a single-pole doublethrow analog switch. A fail-safe semiconductor chip was programmed to shut down the OFS if the power fell to 2.6 V, if there was a failure to oscillate, or if there were current changes indicative of an internal short circuit. Current regulation was set by another semiconductor device that delivered 200 Amp to each pair of electrodes for a total current of 600 Amp. The electrodes were made of standard pacemaker cable and a platinum/iridium tip with a 4.72-mm 2 surface area. One set of three electrodes had black wires and the other set had white wires. A magnetcontrolled reed switch was used to turn the device on or off. When a magnet is on the switch, the device is turned off. When the unit is turned on, it delivers a field of 500 to 600 V/mm and a current density of 42.4 Amp/mm 2 for each electrode. The completed OFS with the magnet on the reed switch was packaged for ethylene oxide gas sterilization. Each unit had the FDA-mandated labeling.
Study Entry Criteria
All patients had to be between 18 and 65 years of age with an acute complete SCI between C-5 and T-10; the injury had to remain complete for at least 48 hours before entry into the study. Patients with penetrating injuries due to gunshot wounds or other devices were excluded. All patients had to have undergone intravenous methylpredinsolone therapy, according to the NASCIS III protocol to be eligible for the trial. 7 In all cases computerized tomography and magnetic resonance imaging studies were required. Complete spinal cord transection as evidenced on magnetic resonance imaging precluded entry into the study. Any spinal cord compression or vertebral instability needed to be treated surgically before study eligibilitythat is, the OFS was not implanted at the same time as the decompression/stabilization procedure. Prisoners, pregnant women, patients with pacemakers, and those incapable of giving informed consent were not eligible for the study. A baseline neurological assessment using the American Spinal Injury Association score (0-5) was recorded for 10 muscle groups bilaterally in all patients who became eligible after meeting the aforementioned criteria. The muscle groups included elbow flexors, wrist extensors, elbow extensors, finger flexors, finger abductors, hip flexors, knee extensors, ankle dorsiflexors, long toe extensors, and ankle plantar flexion. The maximum score was 100. Sensation (light touch and pinprick) was determined bilaterally by using 28 dermatomes (C2-S4) with a 0 to 2 grading scheme. The maximum score was 112 for each modality. Baseline SSEP monitoring demonstrated no conduction from the tibial nerves through the level of injury. A baseline VAS pain score was determined. Thus, baseline neurological, pain, and SSEP assessments were available for all 10 patients to allow monitoring of any changes. We required that the OFS be implanted within 18 days of injury. The OFS device was left in place in the "on" position for 15 weeks (oscillating every 15 minutes) and then surgically explanted, which was required by the FDA. All patients were informed of this prior to consent. On explantation the device was returned to Purdue for analysis of circuitry and electrical function. Ten patients met all entry criteria and provided informed consent.
Placement of the OFS
In the operating room, anesthesia was induced and the patient was placed prone. In cases involving cervical and high thoracic injuries, the patients were placed in a threepoint head fixation apparatus. Prophylactic antibiotic agents were given in all cases. A midline incision was marked using fluoroscopic guidance to allow exposure of the injury level and one laminar segment above and below the injury. A standard exposure of the targeted spinous processes, laminae, and facet joints was obtained. The sterile OFS package was opened on the field and the magnet removed from the switch to activate the device. Each set of the OFS electrodes was checked using an amplitude/voltage meter for accuracy of function and oscillation. Following verification, a subfascial pocket for the stimulator was easily created in the caudal paraspinous musculature to minimize pain/discomfort.
Three white electrodes were placed one segment above the injury, and three black electrodes were placed one segment below. For example, in a case involving a C-6 burst fracture electrodes were placed at C-5 and C-7, whereas in a case involving a T4-5 fracture dislocation the electrodes were implanted at T-3 and T-6. Using a nonabsorbable suture one electrode was sutured to the spinous process and one electrode to the left and right facet capsule area above and below the level of injury (Fig. 2) . The wound received copious antibiotic irrigation and was closed following hemostasis. A postoperative radiograph was obtained to document proper placement (Fig. 3) . for any adverse effects. The FDA was concerned about scar formation and pain in response to the device.
Postimplantation Assessment
At 6 weeks a formal neurological score was determined by the study neurologist and upper-and lower-extremity SSEP measurements were acquired.
Explantation of the OFS
Each patient was returned to surgery at 15 weeks for explantation of the OFS after induction of general anesthesia. Again prophylactic antibiotic agents and antibiotic irrigation were used. The wound was reopened and the stimulator dissected, removed, and tested for function; it was then returned to Purdue to undergo detailed analysis. The wound was closed in a standard surgical fashion. The explantation surgery was performed either as an outpatient procedure or in the hospital with 24-hour observation.
Postexplantation Assessment
Following verification of wound healing, the patient underwent reassessment at 6 months and 1 year; evaluation included obtaining American Spinal Injury Association neurological scores, SSEP status, and VAS pain score.
Statistical Analysis
The significance of the trends in pinprick, light touch, and motor scores was evaluated using two tests: the oneway repeated-measures ANOVA (Kruskal-Wallis test) for paired data in groups of three or more; and the twotailed Wilcoxon test to compare any two groups of paired data in isolation from the other groups. The Pearson rank correlation test was performed for correlation between the different neurological assessments. 
Results
Device and Patient Morbidity
All 10 patients underwent successful placement of the OFS stimulator. Demographic data are summarized in Table 1. Nine of the 10 received methylprednisolone within 3 hours of injury and were treated according to the protocol for 24 hours. The patient in Case 1 received methylprednisolone at 5 hours and was treated for 48 hours. The patients in Cases 1 to 9 underwent internal fixation and/or decompressive surgery prior to study entry, and the patient in Case 10 was treated with closed reduction and halo fixation. In all 10 patients electrodes were placed at one segment above and below the level of injury. Explantation was conducted in all 10 at 15 weeks. All patients returned for the 6-month follow-up assessment. Nine of 10 returned for the 1-year assessment; one patient was lost to follow up after 6 months. At the 1-year follow-up evaluation, the lost patient's Social Security number did not show up on the Social Security death index and thus the patient was presumably alive. There were no complications in any of the device implantation procedures. Blood loss ranged from 50 to 200 ml and no transfusions were required. The mean baseline VAS pain score was 8 (range 7-10); the postoperative status improved. Between the time of explantation and the 1 year follow up, the mean VAS score was maintained at 2 (range 0-4). The device did not negatively affect pain perception in any patient. There was no external wound scarring or keloid formation, and internal scar formation at explantation was not technically problematic. At explantation blood loss ranged from 50 to 150 ml with no transfusions required. Postexplantation there was one case (Case 2) of wound infection that was successfully treated with local wound care and intravenous antibiotic therapy for 2 weeks. Thus the overall infection rate was 5%. Analysis of the OFS at explantation revealed functional devices in nine of 10 cases; the stimulator in Case 2 had apparently stopped between Weeks 14 and 16. The patient suffered no ill effects due to device failure, and electronic analysis revealed early failure resulting from a fragile circuit connection that has already been corrected for future implants. Tables 2 and 3 provide a summary of the raw scores, mean values, and statistics derived from light touch and pinprick sensation testing. The mean recovery of light touch was 25.5 points at 12 months (Table 2) , which was statistically significant compared with baseline according to both statistical methods. Additionally, the patient in Case 7 recovered sexual sensation and pleasurable orgasm. The mean recovery of pinprick sensation was 20.4 points at 12 months (Table 3) , and this too was statistically significant compared with baseline according to both statistical methods. Table 4 provides a summary of raw, mean, and statistical data derived from motor function testing. At 12 months the mean recovery of motor function was 6.3 points, which was statistically significant compared with baseline according to both tests. Only in the patients in Cases 4 and 9 was any lower-extremity function recovered. The patient in Case 9 recovered motor function on the left side below the umbilicus abdominal muscle, Grade 2/5 left iliopsoas muscle function, and Grade 1/5 left extensor hallucis and flexor hallucis function. The patient in Case 4 recovered Grade 2/5 motor function in the right iliopsoas muscle and lower abdominal motor function. The upper-extremity motor recovery was considered functional improvement in Cases 2 and 6 through 8 because it led to improved function with orthotics and/or tendon transfer that resulted in improved function.
Neurological Recovery
The Pearson correlation coefficient analysis revealed a strong linear correlation between the recovery of light touch and pinprick sensation (r = 0.9; p Ͻ 0.0001). There was no correlation between the recovery of light touch and motor function nor pinprick and motor function (r = 0.3 and 0.6; p = 0.33 and 0.6, respectively).
Somatosensory Evoked Potentials
Baseline, 6-week, and 6-month SSEP monitoring was performed in all cases; by 12 months SSEP data were available in nine patients. Of the five cervical cord injuries at baseline, measurable SSEPs were elicited by median nerve stimulation in only one of two arms in four patients (Cases 2 and 6-8) and in one case (Case 10) there were no measureable median nerve SSEPs bilaterally. Of the four
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Oscillating patients in whom arm SSEPs were only unilateral, arm SSEPs improved in two and normalized in two. In the patient with bilaterally absent SSEPs, one arm improved and the other did not. In one patient with cervical injuries minimal posterior tibial nerve SSEPs recovered. Of the five cases involving thoracic injuries, minimal right leg SSEPs were recovered by 1 year, no recovery was observed in three at 1 year, and no recovery was demonstrated in one patient at 6 months (this patient was lost to follow up).
Discussion
The application of oscillating field stimulation in humans was safe and well tolerated by the 10 patients. There were no permanent adverse effects. The risk of wound infection appears to be the same as that associated with any surgery. The technology to manufacture the device is simple, reliable, and readily available. The current and voltage are a power of 10 less than that used for dorsal column spinal cord stimulation when routinely treating chronic pain. The surgical technique is easy and requires no laminotomy. In research dogs we have carefully studied the effect of electrode placement on the magnitude and polarity of the electric field within the spinal cord. 5 This was accomplished using a quadruple electrode arrangement in which two coiled platinum and iridium electrodes served to deliver current, while two other recording electrodes were surgically inserted into spinal cord parenchyma to measure the size and polarity of the field. Provided that one stimulating group of electrodes remained within two or three vertebral segments from the recording site in the cord, field strength was minimally affected (and polarity not at all) when the other stimulating group of electrodes was moved to a distant site. For example, moving one of the electrode groups to the back muscles only reduced the field strength by approximately 10%. Having considered this, we fastened the electrode arrays to the facet joints/spinous processes one or two vertebral segments rostral and caudal to the injury site. Thus, a laminectomy/ facetectomy spanning the injury site would not preclude placement of an OFS.
The efficacy of this therapy remains to be proven. In the third NASCIS trial, in compliant plegic patients in whom there was total baseline sensory loss, the posttreatment pinprick sensation and light-touch sensation scores recovered to 0.6 and 0.5, respectively. All 10 patients in this study were treated precisely as the compliant patients in the third NASCIS. The mean recovery of 20.4 pinprick points is indicative of the therapy's efficacy. The mean recovery of 25.5 light touch points further underscores this efficacy and establishes a basis warranting further study.
In the third NASCIS trial, a mean of three motor function points was restored in the compliant plegic patient in the 24-hour methylprednisolone treatment group. In the present study a mean of 6.3 points was restored, which 1  38  38  58  60  22  2  26  26  26  34  8  3  50  50  58  LTFU  NA  4  70  70  70  72  2  5  46  47  52  52  6  6  20  22  32  32  12  7  18  28  66  111  93  8  20  20  20  44  24  9  66  69  70  75  9  10  12  12  19 again compares favorably, and led to some functional improvement in upper-extremity manipulation. The motor recovery exhibited in these cases deserves further study. Serial SSEP recording has been used to assess functional recovery after graded SCI in the rat, and findings were correlated closely with the extent of clinical recovery. 20 The recovery of SSEPs further supports the sensory recovery that we observed. Whether this is an improvement in the natural history of SSEP recovery is unknown to us because serial SSEPs in patients with complete SCI have never been longitudinally studied. The recovery of SSEPs demonstrated in two patients (Cases 2 and 6) with cervical injury due to bilateral jumped facets could reflect nerve root improvement after reduction and internal fixation, but the improvement obtained in the three patients with C-5 burst fractures is indicative of cord improvement. Certainly the OFSs did not negatively affect SSEPs. Based on these data, the FDA has given us permission to enroll another 10 patients and to evaluate the use of motor evoked potentials to follow these patients serially.
Conclusions
The science underlying the observation that oscillating field stimulation provides both tropic and trophic effects to the injured nervous system is well founded and has been safely applied to the injured spinal cord in humans. If the results obtained in the next 10 patients remain as compelling as those reported here, then a randomized controlled trial will be a logical next step. Our laboratory is actively investigating two other novel approaches in animals that appear synergistic with OFS and can be easily translated to humans in the near future.
